ArticleActa obstetricia et gynecologica Scandinavica2026
Elevated cardiovascular risk associated with hormone replacement therapy: A comprehensive analysis of reproductive factors and atherosclerotic cardiovascular disease outcomes in the UK Biobank cohort.
Article in Acta obstetricia et gynecologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThe cardiovascular effects of hormone replacement therapy (HRT) remain controversial. This study investigated HRT-associated atherosclerotic cardiovascular disease (ASCVD) risk, focusing on reproductive characteristics. MATERIAL AND
methodsThis prospective cohort study analyzed 170 250 women aged 40-69 years from UK Biobank (2006-2024). Cox proportional hazards regression models were employed to estimate ASCVD risk, with stratification by reproductive characteristics (age at menarche, age at menopause, and menopausal status) and age groups (≤45, 46-55, >55 years). Mediation analysis was conducted to examine potential biological pathways through sex hormones, inflammatory markers, and lipid profiles. All analyses were adjusted for demographic factors, socioeconomic status, lifestyle factors, and reproductive history.
resultsDuring follow-up, 11 357 women (6.67%) developed ASCVD. HRT users demonstrated elevated ASCVD risk (adjusted HR 1.13, 95% CI 1.08-1.18, p < 0.001), primarily from increased ischemic stroke. Risk varied by reproductive characteristics: late menarche showed highest risk (HR 1.15, 95% CI 1.08-1.24), followed by late menopause (HR 1.25, 95% CI 1.01-1.54). Perimenopause demonstrated the most pronounced elevation (HR 1.28, 95% CI 1.12-1.46). Women ≤45 years had 77% higher ASCVD risk with HRT use. Dose-response relationships between HRT duration (≥5 years) and ASCVD risk were observed (p
conclusionsHRT increases ASCVD risk with substantial variation by reproductive characteristics. Findings support reproductive profile-based cardiovascular risk assessment for personalized HRT prescribing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.